Novel T-Cell Therapy Promising in Tough-to-Treat Eye Cancer

(MedPage Today) — BERLIN — A single infusion of the investigational PRAME-directed T cell receptor, anzutresgene autoleucel (anzu-cel), showed encouraging antitumor activity in patients with previously treated advanced or metastatic cancer…